← back to search

Lars E. French

ERN Skin · DE
Area of research
Dermatology · Oncology
Research interest
Research interests include Cutaneous Melanoma Detection and Management, Cutaneous lymphoproliferative disorders research, Autoimmune Bullous Skin Diseases, and Drug-Induced Adverse Reactions.
h-index
87
citations
33,247
works
891
NIH funding
primary concept
Medicine
email

Recent publications

Discordance, accuracy and reproducibility study of pathologists’ diagnosis of melanoma and melanocytic tumors
Nature Communications 2025cited by 19position: middledoi
Efficacy and safety of biologics for hidradenitis suppurativa: A network meta‐analysis of phase III trials
Journal of the European Academy of Dermatology and Venereology 2025cited by 14position: middledoi
Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS)
British Journal of Dermatology 2025cited by 8position: middledoi
Benign or Malignant? Ex Vivo Confocal Laser Scanning Microscopy for Bedside Histological Assessment of Melanocytic Lesions
Cancers 2025cited by 7position: middledoi
Interleukin-4 and -13 Gene Expression Profiles in Immune-Related Bullous Pemphigoid Indicate Efficacy of IL-4/IL-13 Inhibitors
Cancers 2025cited by 6position: middledoi
Association of HLA-A*02:01 type with efficacy and toxicity of immune checkpoint inhibitor therapy in melanoma patients: a retrospective cohort study
BMC Cancer 2025cited by 5position: middledoi
LL37 complexed to double-stranded RNA induces RIG-I-like receptor signalling and Gasdermin E activation facilitating IL-36γ release from keratinocytes
Cell Death and Disease 2025cited by 4position: middledoi
59674 Randomized Phase 3 trial of spesolimab in patients with ulcerative pyoderma gangrenosum: A study protocol
Journal of the American Academy of Dermatology 2025cited by 2position: middledoi
Spatial proteomics identifies JAKi as treatment for a lethal skin disease
Nature 2024cited by 120position: middledoi
Federated Learning for Decentralized Artificial Intelligence in Melanoma Diagnostics
JAMA Dermatology 2024cited by 48position: middledoi
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors
European Journal of Cancer 2024cited by 44position: middledoi
Recent progress in Stevens–Johnson syndrome/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment
British Journal of Dermatology 2024cited by 42position: middledoi
Acute generalized exanthematous pustulosis: European expert consensus for diagnosis and management
Journal of the European Academy of Dermatology and Venereology 2024cited by 34position: middledoi
Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient care
Communications Medicine 2024cited by 24position: middledoi
Checkpoint inhibitor–induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level
JAAD International 2024cited by 16position: middledoi
Checkpoint inhibitor‐induced bullous pemphigoid differs from spontaneous bullous pemphigoid
Journal of the European Academy of Dermatology and Venereology 2024cited by 16position: middledoi
MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides
Nature Communications 2024cited by 14position: middledoi
S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens‐Johnson syndrome and toxic epidermal necrolysis) – Part 1: Diagnosis, initial management, and immunomodulating systemic therapy
JDDG Journal der Deutschen Dermatologischen Gesellschaft 2024cited by 14position: middledoi
Unveiling the hidden boundaries: AI‐assisted line‐field optical coherence tomography margin mapping for precise excision of basal cell carcinoma – A step‐by‐step tutorial
Skin Research and Technology 2024cited by 13position: middledoi
Targeting IL-1 controls refractory pityriasis rubra pilaris
Science Advances 2024cited by 12position: middledoi
Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T
European Journal of Cancer 2024cited by 12position: middledoi
Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective Study
Journal of Immunotherapy 2024cited by 11position: middledoi
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Frontiers in Cardiovascular Medicine 2024cited by 11position: middledoi
S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens‐Johnson syndrome and toxic epidermal necrolysis) – Part 2: Supportive therapy of EN in the acute and post‐acute stages
JDDG Journal der Deutschen Dermatologischen Gesellschaft 2024cited by 11position: middledoi
Medical algorithm: Diagnosis and treatment of drug reaction with eosinophilia and systemic symptoms in adult patients
Allergy 2024cited by 10position: middledoi
Exploring the potential of omega‐3 fatty acids in acne patients: A prospective intervention study
Journal of Cosmetic Dermatology 2024cited by 10position: middledoi
Patients’ and dermatologists’ preferences in artificial intelligence–driven skin cancer diagnostics: A prospective multicentric survey study
Journal of the American Academy of Dermatology 2024cited by 9position: middledoi
Skin Cancer Induction by the Antimycotic Drug Voriconazole Is Caused by Impaired DNA Damage Detection Due to Chromatin Compaction
Journal of Investigative Dermatology 2024cited by 7position: middledoi
Using multiple real-world dermoscopic photographs of one lesion improves melanoma classification via deep learning
Journal of the American Academy of Dermatology 2024cited by 6position: middledoi
Characteristics of Gut Microbiota in Rosacea Patients—A Cross-Sectional, Controlled Pilot Study
Life 2024cited by 6position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Daniela Hartmann · LMU Klinikum19 papers (2021–2025)Markus Reinholz · Ludwig-Maximilians-Universität München16 papers (2021–2024)Elke Sattler · Jewish Theological Seminary13 papers (2021–2025)Benjamin Kendziora · München Klinik13 papers (2021–2025)George J. Hruza · UConn Health12 papers (2020–2023)Esther E. Freeman · Harvard University12 papers (2020–2023)Devon E. McMahon · Brigham and Women's Hospital12 papers (2020–2023)Carola Berking · LMU Klinikum10 papers (2018–2025)Lindy P. Fox · Stanford University10 papers (2020–2022)Misha Rosenbach · Carol Davila University of Medicine and Pharmacy10 papers (2020–2023)Pia‐Charlotte Stadler · Ludwig-Maximilians-Universität München8 papers (2021–2023)Benjamin M. Clanner‐Engelshofen · Ludwig-Maximilians-Universität München8 papers (2021–2024)Julia Welzel · Ludwig-Maximilians-Universität München8 papers (2021–2024)Sarah Zierold · Johannes Gutenberg University Mainz8 papers (2022–2024) · 8 papers (2021–2024)Dirk Tomsitz · Technical University of Munich8 papers (2022–2024)Cristel Ruini · Ludwig-Maximilians-Universität München8 papers (2021–2022)Henry W. Lim · Henry Ford Health System8 papers (2020–2023)Jules B. Lipoff · Temple College7 papers (2020–2021)Titus J. Brinker · National Center for Tumor Diseases7 papers (2018–2021)